FUNDAMENTALS · Fundamentals · KR Healthcare

Peptron (087010) Fundamentals 2026 — Revenue Analysis | SniperIQ

Peptron (087010) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩2.41T, trading at ₩103600.00 on the KOE. This SniperIQ fundamentals page covers Peptron's valuation, profitability (net margin -277.8%), revenue (₩5.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩2.41T
Net Margin-277.8%
Revenue (FY25)₩5.6B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Peptron's market cap?

Peptron (087010) has a market capitalization of approximately ₩2.41T, trading at ₩103600.00 on the KOE. Market cap moves with the live share price.

What is Peptron's P/E ratio?

Peptron's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 17.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Peptron?

Peptron runs a net profit margin of -277.8%, a gross margin of 11.7%, and an operating margin of -379.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Peptron generate?

Peptron reported revenue of ₩5.6B for fiscal year 2025, with net income of -₩13.8B and earnings per share (EPS) of -592.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Peptron pay a dividend?

Peptron does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Peptron financially healthy?

Peptron carries a debt-to-equity ratio of 0.22x and a current ratio of 12.19x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Peptron a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Peptron (087010) the key facts are: market cap ₩2.41T, revenue ₩5.6B, 52-week range 98000-392500. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Peptron's full fundamentals live

Get Peptron's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Hanall Biopharma (009420) fundamentals · Hugel (145020) fundamentals · PT Kimia Farma (Persero) (KAEF) fundamentals · ST Pharm (237690) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons